Theodore S. Hong

23.0k total citations · 4 hit papers
368 papers, 11.0k citations indexed

About

Theodore S. Hong is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Theodore S. Hong has authored 368 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 233 papers in Oncology, 164 papers in Surgery and 160 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Theodore S. Hong's work include Pancreatic and Hepatic Oncology Research (102 papers), Colorectal and Anal Carcinomas (79 papers) and Colorectal Cancer Surgical Treatments (68 papers). Theodore S. Hong is often cited by papers focused on Pancreatic and Hepatic Oncology Research (102 papers), Colorectal and Anal Carcinomas (79 papers) and Colorectal Cancer Surgical Treatments (68 papers). Theodore S. Hong collaborates with scholars based in United States, Canada and Germany. Theodore S. Hong's co-authors include David P. Ryan, Nabeel Bardeesy, Jennifer Y. Wo, Andrew X. Zhu, Lawrence S. Blaszkowsky, Jeffrey W. Clark, Cristina R. Ferrone, Eunice L. Kwak, Carlos Fernández‐del Castillo and Paul M. Harari and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Theodore S. Hong

348 papers receiving 10.8k citations

Hit Papers

4 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pancreatic Adenocarcinoma

2014 1.7k citations David P. Ryan, Theodore S. Hong et al. profile →
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

2016 653 citations Theodore S. Hong et al. profile →
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma

2018 362 citations Janet E. Murphy, Jennifer Y. Wo et al. profile →
Neoadjuvant therapy for pancreatic cancer

2023 199 citations Theodore S. Hong et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Theodore S. Hong United States	45	6.6k	4.3k	3.9k	2.0k	1.6k	368	11.0k
Howard Safran United States	47	5.7k 0.9×	3.9k 0.9×	2.7k 0.7×	1.5k 0.7×	498 0.3×	229	9.2k
Christopher G. Willett United States	71	9.6k 1.5×	7.7k 1.8×	9.1k 2.4×	1.8k 0.9×	1.7k 1.1×	308	17.4k
Ross A. Abrams United States	54	10.0k 1.5×	6.3k 1.5×	6.0k 1.6×	2.3k 1.1×	712 0.4×	181	14.5k
Cornelis Verhoef Netherlands	53	6.1k 0.9×	3.1k 0.7×	3.3k 0.8×	1.3k 0.6×	501 0.3×	476	11.0k
Prajnan Das United States	48	6.0k 0.9×	3.5k 0.8×	5.6k 1.5×	789 0.4×	876 0.5×	323	9.8k
Christopher H. Crane United States	70	13.8k 2.1×	7.9k 1.8×	9.0k 2.3×	3.4k 1.6×	1.4k 0.9×	394	18.5k
James W. Welsh United States	50	4.5k 0.7×	4.2k 1.0×	1.7k 0.4×	1.3k 0.6×	1.0k 0.6×	247	9.6k
Karin Haustermans Belgium	64	7.3k 1.1×	9.6k 2.2×	6.4k 1.7×	2.3k 1.1×	2.9k 1.8×	383	18.5k
Mitchell Machtay United States	56	4.1k 0.6×	7.9k 1.8×	4.4k 1.1×	941 0.5×	2.6k 1.6×	299	14.3k
Umberto Ricardi Italy	48	2.7k 0.4×	4.8k 1.1×	2.3k 0.6×	906 0.4×	2.3k 1.5×	362	10.0k

Countries citing papers authored by Theodore S. Hong

Since Specialization

Citations

This map shows the geographic impact of Theodore S. Hong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Theodore S. Hong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Theodore S. Hong more than expected).

Fields of papers citing papers by Theodore S. Hong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Theodore S. Hong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Theodore S. Hong. The network helps show where Theodore S. Hong may publish in the future.

Co-authorship network of co-authors of Theodore S. Hong

This figure shows the co-authorship network connecting the top 25 collaborators of Theodore S. Hong. A scholar is included among the top collaborators of Theodore S. Hong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Theodore S. Hong. Theodore S. Hong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wehrenberg-Klee, Eric, Antoine Desîlets, Marlana Orloff, et al.. (2025). Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients. The Oncologist. 30(10).

Kim, Daniel W., Grace C. Lee, Aparna R. Parikh, et al.. (2025). Severe Lymphopenia Predicts Poorer Survival in Patients With Rectal Cancer Undergoing Neoadjuvant Chemoradiation. The Cancer Journal. 31(1).

Bhutani, Manoop S., Amol Narang, Kai Ding, et al.. (2024). EUS-guided hydrogel injection to separate pancreatic head carcinoma from duodenum for enhanced radiotherapy: Multi-site feasibility study. SHILAP Revista de lepidopterología. 12(7). E861–E867. 1 indexed citations

Koenig, Julie L., Beow Y. Yeap, Jeffrey W. Clark, et al.. (2023). A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable pancreatic adenocarcinoma.. Journal of Clinical Oncology. 41(16_suppl). 4143–4143. 2 indexed citations

Dasari, Arvind, Scott Kopetz, Samuel A. Jacobs, et al.. (2023). Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.. Journal of Clinical Oncology. 41(16_suppl). TPS3634–TPS3634. 1 indexed citations

Boucher, Yves, Jessica M. Posada, Sonu Subudhi, et al.. (2023). Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer. Clinical Cancer Research. 29(8). 1605–1619. 30 indexed citations

Monfared, Yousef Khazaei, Pedram Heidari, Samuel J. Klempner, et al.. (2023). DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair. Pharmaceutics. 15(12). 2761–2761. 20 indexed citations

Wyrwicz, Lucjan, Mark Saunders, Marcia Hall, et al.. (2023). AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiotherapy and Oncology. 185. 109669–109669. 5 indexed citations

Hall, William A., Jiahe Li, Y. Nancy You, et al.. (2023). Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma. Journal of Clinical Oncology. 41(29). 4643–4651. 15 indexed citations

10.

Guo, Jimmy A., Hannah I. Hoffman, Stuti G. Shroff, et al.. (2021). Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection. Clinical Cancer Research. 27(10). 2807–2815. 16 indexed citations

11.

Tchelebi, Leila T., Cathy Eng, Craig Messick, et al.. (2021). Current treatment and future directions in the management of anal cancer. CA A Cancer Journal for Clinicians. 72(2). 183–195. 17 indexed citations

12.

Kamran, Sophia C., Christine E. Eyler, Jochen K. Lennerz, et al.. (2020). Evolutionary Analysis of Pre- and Post-treatment Molecular Diversity in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiation (CRT) and a KRAS Mutation-targeted Radiosensitizer. International Journal of Radiation Oncology*Biology*Physics. 108(3). S57–S57.

13.

Kamran, Sophia C., Jochen K. Lennerz, Claire A. Margolis, et al.. (2019). Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clinical Cancer Research. 25(18). 5561–5571. 62 indexed citations

14.

Wo, Jennifer Y., John P. Plastaras, James M. Metz, et al.. (2019). Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. International Journal of Radiation Oncology*Biology*Physics. 105(1). 90–95. 21 indexed citations

15.

Han, Jing, Lynnette Marcar, Joshua C. Black, et al.. (2017). Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin–EGFR Pathway. Cancer Research. 77(8). 2018–2028. 77 indexed citations

16.

Liu, Qi, Meng Wang, Jing Han, et al.. (2015). Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers. Molecular Cancer Research. 13(4). 713–720. 29 indexed citations

17.

Kwak, Eunice L., Leanne G. Ahronian, Giulia Siravegna, et al.. (2015). Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET -Amplified Esophagogastric Cancer. Cancer Discovery. 5(12). 1271–1281. 138 indexed citations

18.

Sabbatino, Francesco, Vincenzo Villani, Jennifer H. Yearley, et al.. (2015). PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clinical Cancer Research. 22(2). 470–478. 162 indexed citations

19.

Chan, Carlos H.F., Tristan Penson, Yosef Landesman, et al.. (2015). XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer. Clinical Cancer Research. 22(7). 1663–1673. 36 indexed citations

20.

Wolfgang, John A., et al.. (2011). Motion Management For Proton SBRT Liver Treatment: Use Of Serial 4DCT To Determine Optimal Localization Strategy. International Journal of Radiation Oncology*Biology*Physics. 81(2). S884–S885. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact